In its first full year of operation since it was launched as a for-profit division of the American College of Radiology, ACR Image Metrix exceeded its goals by initiating projects for over 12 drug and device companies.
American College of Radiology Image Metrix Completes Successful First Year
(Philadelphia, PA; September 23, 2008) – In its first full year of operation since it was launched as a for-profit division of the American College of Radiology, ACR Image Metrix exceeded its goals by initiating projects for over 12 drug and device companies.
“We are very pleased with the success of our business model as a state-of-the-art core lab and our validated IT platform,” said Stephen King, ACR Image Metrix chief operating officer. “There is a significantly higher level of awareness for the value imaging expertise can add to clinical trials, as well as a growing understanding of the role ACR Image Metrix can play in expediting clinical trials.”
“Our unique heritage borne out of the ACR and ACRIN organizations has shown to give us tremendous creditability from the start,” said Michael J. Morales, ACR Image Metrix general manager. “It positions us as having both the scientific and operational horsepower to compete at a very high level in the CRO marketplace.”
The ACR Image Metrix advantage resides within its access to the American College of Radiology, a 32,000-member professional organization, and to the ACR Imaging Network (ACRIN), which has participated in clinical trials ranging from 65 to more than 50,000 subjects and involving more than 500 million images.
Morales said that Image Metrix will concentrate on CROs, pharmaceutical, biotech, and medical device companies to provide services in Phase I-III clinical trials.
The state-of-the-art imaging core laboratories of Image Metrix provide clients access to the latest technologies including CT, MRI/MRS, and PET/nuclear medicine. Recent trials have focused on the capacity of molecular and functional imaging to serve as biomarkers of the effectiveness of anticancer treatments.
“We’re ahead of where we wanted to be in our growth strategy,” Morales said. “We’re looking forward to accelerated growth in year two.”
About Image Metrix
Image Metrix, a division of the American College of Radiology, is in the forefront of applying imaging techniques as a predictive and prognostic biomarker for clinical trials. The key to increasing the efficiency of drug development programs is the integration of the appropriate imaging modality.
The world-class team of physicians and scientists at ACR Image Metrix works with pharmaceutical, biotech and medical device companies to increase the efficiency of drug development programs by integrating the appropriate imaging modalities. Their years of experience and proven expertise in employing state-of-the-art technologies provide a complete line of imaging services.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.